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Few studies have evaluated the role of antibacterial prophylaxis during neutropenia in patients with multiple
myeloma undergoing autologous hematopoietic stem cell transplantation (HSCT). At our center, levoﬂoxacin
prophylaxis was initiated in June 2006 in patients with myeloma who were undergoing autologous HSCT. We
compared the incidence of bloodstream infection (BSI) and fever and neutropenia (FN) within 30 days of
transplantation before (January 2003 to May 2006) and after (June 2006 to April 2010) the initiation of
levoﬂoxacin prophylaxis in patients undergoing autologous HSCT for myeloma. We also compared rates of BSI
and FN during the same time periods in autologous HSCT recipients with lymphoma who did not receive
antibacterial prophylaxis during either time period. After the initiation of levoﬂoxacin prophylaxis, the BSI
rate decreased from 41.2% (49 of 119) to 14.7% (23 of 156) and the rate of FN decreased from 91.6% to 60.9% in
patients with myeloma (P < .001, for each). In contrast, rates of BSI (43.1% versus 47.3%; P ¼ .50) and FN (98.8%
versus 97.1%; P ¼ .63) did not change in patients with lymphoma. Levoﬂoxacin prophylaxis was independently
associated with decreased odds of BSI (odds ratio, .27; 95% conﬁdence interval, .14 to .51; P < .001) and FN
(odds ratio, .18; 95% conﬁdence interval, .09 to .36; P < .001) in multivariate analysis. Patients with myeloma
had a nonsigniﬁcant increase in the risk of BSI due to levoﬂoxacin-resistant Enterobacteriaceae (5% versus 1%,
P ¼ .08) and Clostridium difﬁcile infection (7% versus 3%, P ¼ .12) after the initiation of levoﬂoxacin prophylaxis
but did not have higher rates of BSI due to other resistant bacteria. Levoﬂoxacin prophylaxis is associated with
decreased risk of BSI and FN in patients with myeloma undergoing autologous HSCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
High-dose chemotherapy combined with autologous he-
matopoietic stem cell transplantation (HSCT) is an important
component of the treatment of patients with multiple
myeloma [1]. Neutropenia is a universal complication of
autologous HSCT and combines with chemotherapy-induced
mucositis to establish a high-risk setting for bacteremia [2,3].
To decrease the risk of bacterial infection, guidelines of theedgments on page 1813.
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15.06.017
ty for Blood and Marrow Transplantation.Infectious Diseases Society of America and American Society
for Blood and Marrow Transplantation recommend consid-
ering the administration of antibacterial prophylaxis during
chemotherapy-induced neutropenia in patients with antici-
pated neutropenic periods of at least 7 days [4,5].
These recommendations are largely based on 2 random-
ized, placebo-controlled trials of levoﬂoxacin in patients
with cancer and neutropenia that were conducted from 1999
to 2003 and demonstrated lower rates of fever and neu-
tropenia (FN) and bacterial infections, but not decreased
mortality, in patients receiving levoﬂoxacin prophylaxis
[6,7]. However, during the decade since these trials
were conducted, ﬂuoroquinolone resistance has become
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ﬂuoroquinolone-resistant Clostridium difﬁcile has emerged
[10]. These developments merit a reassessment of the role of
levoﬂoxacin prophylaxis in patients with neutropenia.
Furthermore, the applicability of results from these land-
mark trials to patients with multiple myeloma undergoing
autologous HSCT is unclear, as very few of these patients
were evaluated in these trials. Two subsequent, single-
center, randomized trials have been conducted to assess
the role of ﬂuoroquinolone prophylaxis in patients receiving
autologous HSCT, but these studies are limited by small
sample sizes and/or the use of multiple prophylactic anti-
microbial agents [11,12].
Before June 2006, antibacterial prophylaxis was not
administered to patients undergoing autologous HSCT at
our center. In response to 2 deaths in patients with multiple
myeloma from septic shock due to ﬂuoroquinolone-
susceptible Gram-negative bacteria, levoﬂoxacin prophy-
laxis was initiated in June 2006 in patients with myeloma
undergoing autologous HSCT but not in patients receiving
autologous HSCT for other indications, such as lymphoma.
This selective intervention established a unique setting to
evaluate the efﬁcacy and adverse effects related to the use
of levoﬂoxacin prophylaxis in patients undergoing autolo-
gous HSCT.
MATERIALS AND METHODS
Study Design
This is a single-center, retrospective, cohort study at New York-
Presbyterian Hospital/Weill Cornell Medical Center that consists of 2 study
periods. In period 1 (January 2003 to May 2006), neither patients with
multiple myeloma nor patients with lymphoma received antibacterial pro-
phylaxis during their autologous transplantation admission. In period 2
(June 2006 to April 2010), patients with myeloma who underwent autolo-
gous HSCT received 500 mg of oral levoﬂoxacin daily from 1 day before their
stem cell infusion until recovery from neutropenia. Patients with lymphoma
who underwent autologous HSCT continued not to receive antibacterial
prophylaxis during period 2. Multiple transplantations involving individual
patients were eligible for analysis, provided that the patient did not have a
prior transplantation within the previous 90 days.
The primary objective of the study was to compare the incidence of
(1) bloodstream infection (BSI) and (2) FN within 30 days of trans-
plantation in period 1 versus period 2 in patients with myeloma and in
patients with lymphoma. We also assessed the incidence of BSI and FN
during each year of the study in both patient populations. Secondary ob-
jectives of the study were to compare rates of BSIs due to speciﬁc bacteria,
including multidrug-resistant (MDR) pathogens, and rates of C. difﬁcile
infection within 90 days of transplantation between time periods in both
patient groups.
Furthermore, for autologous HSCT recipients with multiple myeloma,
we reviewed medical records to compare the following variables between
patients who received and did not receive levoﬂoxacin prophylaxis: de-
mographics, myeloma characteristics, comorbidities [13], baseline serum
albumin and creatinine levels, recent C. difﬁcile infection, conditioning
regimen, central venous catheter type, number of CD34 cells infused, and
duration of neutropenia. We then conducted multivariate analyses to
determine whether levoﬂoxacin prophylaxis was independently associated
with the risk of BSI or FN in patients with myeloma. Finally, we compared
the following additional outcomes for myeloma patients who received and
did not receive levoﬂoxacin prophylaxis: developing a BSI that was associ-
ated with severe sepsis or an intensive care unit (ICU) admission, a micro-
biologically documented infection other than bacteremia or an invasive
fungal infection, duration of hospitalization, readmission within 90 days of
the transplantation, mortality within 30 and 90 days of the transplantation,
and mortality related to sepsis.
Deﬁnitions and Study Procedures
Fever was deﬁned as a temperature  38.0C and neutropenia was
deﬁned as an absolute neutrophil count  500 cells/mL. Common skin
commensals (coagulase-negative staphylococci, Bacillus and Corynebacte-
rium spp. other than C. jeikeium) were only considered causes of BSI if iso-
lated from at least 2 sets of blood cultures collected on the same day or on
consecutive days.During both study periods, HSCT recipients with myeloma and lym-
phoma were placed in private rooms on the same inpatient transplant unit
until neutrophil engraftment. They were cared for by the same medical staff
and received the same supportive care practices (other than antibacterial
prophylaxis), including infection control practices recommended by the
Centers for Disease Control and Prevention [14]. Intravenous melphalanwas
administered as a conditioning regimen at a dose of 200mg/m2, divided into
2 doses on days 2 and days 1. The melphalan dose was reduced to 140
mg/m2 in frail elderly patients and in patients with a creatinine clearance <
60 mL/minute.
For initial work-up of FN, blood cultures (1 aerobic and 1 anaerobic
bottle per set) were obtained from peripheral blood and each central venous
catheter lumen. Subsequent blood cultures were drawn daily for persistent
fever. Piperacillin-tazobactam was the primary agent used for FN during
both time periods and broad-spectrum b-lactam therapy was typically
continued until resolution of FN. All patients received prophylactic ﬂucon-
azole and valacyclovir and daily ﬁlgrastim injections until resolution of
neutropenia. All patients had central venous catheters that were typically
placed on the day of admission for transplantation and removed upon
discharge from the transplantation admission, unless intravenous medica-
tions were required after discharge.
BacT/ALERT 3D (BioMérieux Inc., Durham, NC) was the automated
blood culture system used during both study periods. Species identiﬁca-
tion and antimicrobial susceptibility testing of bloodstream isolates were
primarily performed by Vitek II (BioMérieux Inc.), according to Clinical and
Laboratory Standards Institute recommendations [15]. From 2003 to 2009,
the Wampole Clostridium difﬁcile Tox A/B Microplate Assay (Alere, Orlando,
FL) was used to detect C. difﬁcile toxin from stool. In 2010, more sensitive
assays were employed to detect C. difﬁcile toxin, and thus patients who
received a transplant in 2010 were excluded from the analysis of C. difﬁcile
infection rates.Statistical Analysis
Proportions were compared using 2-tailed chi-squared or Fisher exact
tests and P  .05 was considered statistically signiﬁcant. Continuous vari-
ables were expressed as median values with interquartile ranges and
compared by the Wilcoxon rank-sum test. Factors associated with devel-
oping a BSI or FN in patients with multiple myeloma were evaluated in
univariate and multivariate logistic regression models. All variables with a P
value  .10 in the univariate model, as well as age, years since myeloma
diagnosis, prior HSCT, and duration of neutropenia, were included in the
multivariate model. STATA, version 12.0 (StataCorp, College Station, TX) was
used for statistical analysis.RESULTS
Patients and Rates of BSI and FN in Period 1 and Period 2
Four hundred seventy-ﬁve autologous HSCTs were
performed during the study period. Of these, 275 trans-
plantations for multiple myeloma and 190 transplantations
for lymphoma were eligible for analysis. None of the 119
patients with myeloma and none of the 88 patients with
lymphoma in period 1 received antibacterial prophylaxis. In
period 2, 148 of the 156 myeloma patients received levo-
ﬂoxacin prophylaxis (eight patients had a levoﬂoxacin
allergy or prior intolerance) and none of the 102 lymphoma
patients received antibacterial prophylaxis.
The incidence of BSI within 30 days of transplantation in
patients with myeloma decreased from 41.2% in period 1
(before levoﬂoxacin prophylaxis) to 14.7% in period 2 (after
levoﬂoxacin prophylaxis; P < .001) (Table 1). Patients with
lymphoma who did not receive antibacterial prophylaxis
during either time period had no signiﬁcant change in BSI
incidence (43.1% in period 1 versus 47.3% in period 2; P¼ .50).
Similarly, the incidence of FN in patients with myeloma
decreased from 91.6% in period 1 to 60.9% in period 2
(P < .001). The incidence of FN did not change in patients
with lymphoma (98.8% versus 97.1%; P ¼ .63). The decreases
in rates of BSI and FN in patients with myeloma occurred
immediately after the intervention of ﬂuoroquinolone pro-
phylaxis and were sustained during each subsequent study
year (Figure 1A and B).
Table 1
Comparisons of the Microbiology of BSI and Clostridium difﬁcile Infection Rates between Period 1 (January 2003 to May 2006) and Period 2 (June 2006 to April
2010) in Patients with Multiple Myeloma and Lymphoma Who Underwent Autologous Stem Cell Transplantation
Infection Types Myeloma Period 1
(n ¼ 119)
Myeloma Period 2*
(n ¼ 156)
P Valuey Lymphoma Period 1
(n ¼ 88)
Lymphoma Period 2
(n ¼ 102)
P Valuey
Any BSI 49 (41) 23 (15) <.001 38 (43) 49 (47) .50
Gram-positive bacteremia 37 (31) 15 (10) <.001 24 (27) 26 (26) .78
Staphylococcus aureus 6 (5) 4 (3) 1 (1) 5 (5)
Methicillin-susceptible 2 (2) 0 1 (1) 4 (4)
Methicillin-resistant 4 (3) 4 (3) 0 1 (1)
Coagulase-negative staphylococci 11 (9) 0 <.001 7 (8) 4 (4)
VGS 12 (10) 4 (3) .008 5 (6) 10 (10)
Penicillin-nonsusceptible VGS 3 (3) 3 (2) 3 (3) 2 (2)
Enterococci 6 (5) 6 (5) 10 (11) 9 (9)
Vancomycin-susceptible 2 (2) 1 (1) 3 (3) 2 (2)
Vancomycin-resistant 4 (3) 5 (3) 7 (8) 7 (7)
Gram-negative bacteremia 13 (11) 11 (7) .26 28 (32) 34 (33) .82
Enterobacteriaceae 11 (9) 11 (7) 26 (30) 30 (29)
Escherichia coli 7 (6) 8 (5) 9 (10) 14 (14)
Enterobacter cloacae 2 (2) 2 (1) 2 (2) 1 (1)
Klebsiella pneumoniae 2 (2) 0 13 (15) 16 (16)
Levoﬂoxacin-resistant 1 (1) 8 (5) .08 7 (8) 2 (2) .08
Ceftriaxone-resistant 0 1 (1) 5 (6) 1 (1) .10
Carbapenem-resistant 0 1 (1) 0 0
Pseudomonas aeruginosa 0 0 0 0
Candidemia 2 (2) 0 0 1 (1)
Clostridium difﬁcile infection 3 (3) 9 (7)z .12 4 (5) 6 (6)z .75
Variables are presented as n (%) of total.
* Levoﬂoxacin prophylaxis was administered to these patients from 1 day before stem cell infusion until neutrophil engraftment.
y Blank values indicate a P value of > .10.
z In period 2, the incidence of C. difﬁcile infection was only evaluated in patients who underwent transplantation from June 2006 to December 2009 because
testing for C. difﬁcile changed in 2010 from an ELISA-based to a PCR-based method.
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Period 1 versus Period 2
The incidence of Gram-positive bacteremia in patients
with myeloma decreased from 31% in period 1 to 10% in
period 2 (P< .001) (Table 1). This decrease was largely due to
decreases in rates of bacteremia caused by coagulase-
negative staphylococci (9% versus 0%; P < .001) and vir-
idans group streptococci (VGS; 10% versus 3%; P ¼ .008).
There were no changes in rates of bacteremia caused by
methicillin-resistant Staphylococcus aureus, penicillin-
nonsusceptible VGS, or vancomycin-resistant enterococci.
There was no signiﬁcant change in the incidence of Gram-
negative bacteremia in myeloma patients between period 1
and period 2 (11% versus 7%; P ¼ .26). There was a trend
towards an increase in the rate of BSI due to levoﬂoxacin-
resistant Enterobacteriaceae (1% versus 5%; P ¼ .08), but no
trends towards increased rates of bacteremia caused by otherFigure 1. Incidence of (A) bloodstream infection and (B) fever and neutropenia wit
myeloma and patients with lymphoma, by year of transplantation.MDR Gram-negative bacteria. In patients with lymphoma,
there were no signiﬁcant changes in the incidence of
bacteremia due to any speciﬁc bacterial pathogen between
period 1 and period 2.
The incidence of C. difﬁcile infection within 90 days of
transplantation in patients with myeloma increased from 3%
in period 1 to 7% in period 2 (P¼ .12) (Table 1). This incidence
did not change during these 2 periods in patients with
lymphoma.
Characteristics and Outcomes of Patients with Multiple
Myeloma
Patients with myeloma who received levoﬂoxacin pro-
phylaxis (n ¼ 148) received a median of 9 days of levo-
ﬂoxacin. These patients were older (median age, 59 years
versus 56 years; P ¼ .009) (Table 2) and had lower baseline
serum albumin levels (3.2 versus 3.6 mg/dL; P < .001) thanhin 30 days of autologous stem cell transplantation in patients with multiple
Table 2
Characteristics of Patients with Multiple Myeloma Who Received and Did
Not Receive Prophylactic Levoﬂoxacin during Neutropenia after Autologous
HSCT*
Characteristics No Levoﬂoxacin
Prophylaxis
(n ¼ 127)
Levoﬂoxacin
Prophylaxis
(n ¼ 148)
P Value
Demographics
Age, yr 56 (49-61) 59 (53-64) .009
Female sex 56 (44) 74 (50) .33
Myeloma characteristics
Immunoglobulin type .12
IgG 66 (52) 93 (63)
IgA 27 (21) 22 (15)
None (light chain) 34 (27) 31 (21)
Other 0 (0) 2 (1)
Light-chain type
Kappa 80 (63) 85 (57) .35
Lambda 47 (37) 63 (43)
Years since diagnosis 1 (1-3) 1 (1-2) .72
Previous HSCT 23 (18) 16 (11) .08
Comorbidities
Charlson comorbidity index
score
2 (2-3) 2 (2-3) .37
Myocardial infarction 13 (10) 5 (3) .02
Congestive heart failure 4 (3) 1 (1) .19
Cerebrovascular disease 3 (2) 3 (2) 1.00
COPD 1 (1) 2 (1) 1.00
Connective tissue disease 1 (1) 5 (3) .22
Liver disease 1 (1) 5 (3) .22
Diabetes 16 (13) 13 (9) .31
Kidney disease 13 (10) 8 (5) .13
Solid tumor 6 (5) 10 (7) .47
Baseline serum creatinine
(mg/dL)
.9 (.7-1.3) .8 (.7-1.1) .19
Baseline serum albumin
(mg/dL)
3.6 (3.3-4.0) 3.2 (2.9-3.5) <.001
C. difﬁcile infection within
90 d before HSCT
1 (1) 1 (1) 1.00
Transplantation characteristics
Conditioning regimen .02
Melphalan (200 mg/m2) 112 (88) 112 (76)
Melphalan (dose < 200
mg/m2)
8 (6) 24 (16)
Melphalan þ
(bendamustine
or carmustine)
7 (6) 12 (8)
CVC type .30
PICC line 29 (23) 42 (28)
Tunneled CVC 98 (77) 106 (72)
No. of CD34 cells infused
( 106/kg)
6.5 (4.7-9.2) 5.1 (4.1-7.2) <.001
Duration of neutropenia, d 7 (6-9) 7 (6-8) .03
COPD indicates chronic obstructive pulmonary disease; CVC, central venous
catheter; PICC, peripherally inserted central catheter.
This table analyzes 275 transplantations performed among 263 unique
patients.
All categorical variables are expressed as n (%) of total. All continuous var-
iables are expressed as median (interquartile range).
* Eight patients in period 2 did not receive levoﬂoxacin prophylaxis
because of allergy or intolerance.
Table 3
Outcomes of Patients with Multiple Myeloma Who Received and Did Not
Receive Prophylactic Levoﬂoxacin during Neutropenia after HSCT
Outcomes No Levoﬂoxacin
Prophylaxis
(n ¼ 127)
Levoﬂoxacin
Prophylaxis
(n ¼ 148)
P Value
FN 114 (90) 90 (61) <.001
BSI
BSI before neutrophil
engraftment
48 (38) 19 (13) <.001
BSI within 30 d of
transplantation
52 (41) 20 (14) <.001
Gram-positive bacteremia 38 (30) 14 (9) <.001
Gram-negative
bacteremia
16 (13) 8 (5) .04
Fungemia 2 (2) 0 .21
BSI associated with severe
sepsis [16]
9 (7)* 8 (5)y .56
BSI associated with ICU
admission
8 (6) 5 (3) .27
Microbiologically documented
infection other than
bacteremia within 30 d of
transplantation
11 (9) 16 (11) .55
Invasive fungal infection
within 30 d
2 (2) 2 (1) 1.00
C. difﬁcile infection within 90
d of transplantationz
4 (3)x 9 (7)k .17
Duration of hospitalization, d 20 (18-27) 18 (17-21) .001
Readmission within 90 d of
transplantation
32 (25) 24 (16) .07
Mortality
Within 30 d of
transplantation
4 (3) 4 (3) 1.00
Within 90 d of
transplantation
8 (7) 4 (3) .13
Sepsis-related mortality{ 5 (4) 3 (2) .48
All categorical variables are expressed as n (%) of total. All continuous var-
iables are expressed as median (interquartile range).
* BSI etiologies associated with severe sepsis in patients who did not
receive levoﬂoxacin prophylaxis: polymicrobial (n ¼ 4), Streptococcus mitis
(n ¼ 2), vancomycin-resistant Enterococcus faecium (n ¼ 1), Escherichia coli
(n ¼ 1), and Klebsiella pneumoniae (n ¼ 1).
y BSI etiologies associated with severe sepsis in patients who received
levoﬂoxacin prophylaxis: E. coli (n ¼ 3), methicillin-resistant Staphylococcus
aureus (n ¼ 2), polymicrobial (n ¼ 2), and K. pneumoniae (n ¼ 1).
z In period 2, the incidence of C. difﬁcile infection was only evaluated in
patients who underwent transplantation from June 2006 to Dec 2009
because testing for C. difﬁcile changed in 2010 from an ELISA-based to a PCR-
based method.
x Three patients were treated with 10 to 14 days of oral metronidazole
and 1 was treated with 21 days of oral vancomycin. Three of these patients
had C. difﬁcile recurrence after treatment.
k Six patients were treated with 10 to 14 days of oral metronidazole and 3
were treated with 10 to 21 days of oral vancomycin. One of these patients
had C. difﬁcile recurrence after treatment.
{ Causes of death unrelated to sepsis were respiratory failure of unknown
etiology, acute respiratory distress syndrome after inﬂuenza B infection,
intra-abdominal hemorrhage, and intracerebral hemorrhage.
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There were no statistically signiﬁcant differences between
groups in myeloma characteristics, rates of prior HSCT or
C. difﬁcile infection, Charlson comorbidity index score, and
baseline serum creatinine. Melphalan was used as the sole
conditioning agent in >90% of transplantations in both
groups, although patients who received levoﬂoxacin pro-
phylaxis were less likely to receive a 200 mg/m2 dose of
melphalan (88% versus 76%; P ¼ .02). Patients who received
levoﬂoxacin prophylaxis had a lower median number of
CD34 cells infused (5.1  106/kg versus 6.4  106/kg, P <
.001). Despite receiving fewer CD34 cells, they had amarginally decreased duration of neutropenia, although the
median duration was 7 days in both groups.
Myeloma patients who received levoﬂoxacin prophylaxis
were less likely to develop FN (61% versus 90%; P < .001)
(Table 3), any BSI within 30 days of the transplantation
(14% versus 41%; P < .001), and Gram-positive bacteremia
(9% versus 30%; P < .001) than those who did not receive
levoﬂoxacin prophylaxis. Although there was no difference
in rates of Gram-negative bacteremia between period 1 and
period 2, not all myeloma patients received levoﬂoxacin
prophylaxis in period 2. When myeloma patients who
received levoﬂoxacin prophylaxis were compared with
those who did not receive antibacterial prophylaxis, the rate
of Gram-negative bacteremia was lower in patients who
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signiﬁcant differences in rates of BSI associated with severe
sepsis [16] or ICU admission, invasive fungal infection, or
microbiologically documented infection other than bacter-
emia within 30 days of the transplantation. Seven percent of
patients who received levoﬂoxacin prophylaxis developed
C. difﬁcile infection within 90 days of the transplantation,
compared with 3% in patients who did not receive pro-
phylaxis (P ¼ .17). There was a shorter median duration of
hospitalization in patients who received levoﬂoxacin pro-
phylaxis (18 days versus 20 days, P ¼ .001) and a trend to-
wards a lower readmission rate (16% versus 25%, P ¼ .07),
but no differences in 30-day, 90-day, or sepsis-related
mortality.
Factors Associated with BSI and FN in Patients with
Multiple Myeloma
In univariate analysis, factors associated with developing
a BSI within 30 days of the transplantation included having
light-chaineonly disease, increased number of years since
myeloma diagnosis, and increased baseline serum creatinine
and duration of neutropenia, whereas levoﬂoxacin prophy-
laxis was associated with decreased odds of BSI. In a multi-
variate model, levoﬂoxacin prophylaxis was independently
associated with a 73% decrease in odds of developing a BSI
(odds ratio, .27; 95% conﬁdence interval, .14 to .51; P < .001)
(Table 4).
Factors associated with developing FN within 30 days of
the transplantation in univariate analysis included having a
higher Charlson comorbidity index score and having an
increased baseline serum creatinine and duration of neu-
tropenia, whereas levoﬂoxacin prophylaxis was associatedTable 4
Factors Associated with Developing BSI and FN within 30 Days after Autologous H
Variables BSI: Univariate
Analysis
OR (95% CI)
P BSI: M
Analy
OR (9
Levoﬂoxacin prophylaxis .23 (.13-.41) <.001 .27
Age, per yr increase .98 (.95-1.01) .17 .98
Female sex 1.45 (.85-2.50) .17
Immunoglobulin type
IgG Reference Refer
IgA 1.33 (.63-2.78) .45 1.13
Light chain only 2.30 (1.23-4.30) .009 2.09
Lambda light chain (versus kappa) .68 (.39-1.20) .18
Year since diagnosis, per year increase 1.09 (1.00-1.19) .047 .99
Previous HSCT 3.28 (1.63-6.59) .001 2.11
Charlson comorbidity index score, per unit
increase
.98 (.73-1.31) .88
Myocardial infarction 1.88 (.70-5.05) .21
Congestive heart failure .70 (.08-6.37) .75
Liver disease .56 (.06-4.86) .60
Diabetes .89 (.36-2.17) .79
Kidney disease 1.83 (.72-4.61) .20
Solid tumor .64 (.18-2.30) .49
Baseline serum creatinine, per mg/dL increase 1.30 (1.05-1.60) .015 1.18
Baseline serum albumin, per mg/dL increase 1.45 (.87-2.42) .16
Conditioning regimen
Melphalan 200 mg/m2 Reference
Lower dose melphalan 1.12 (.49-2.56) .79
Melphalan þ other agent 1.02 (.35-2.96) .97
PICC line (versus tunneled CVC) .85 (.46-1.60) .62
CD34 cells infused, per 106/kg increase 1.02 (.98-1.07) .37
Duration of neutropenia, per d increase 1.16 (1.06-1.27) .001 1.13
OR indicates odds ratio; CI, conﬁdence interval; N/A, not applicable.
* Variables included in the multivariate model: age, years since diagnosis, previo
analysis.
y Unable to calculate odds ratio or P value because all patients with kidney disewith decreased odds of FN. In a multivariate model, levo-
ﬂoxacin prophylaxis was independently associated with an
82% decrease in odds of developing FN (odds ratio, .18; 95%
conﬁdence interval, .09 to .36; P < .001).
DISCUSSION
The selective intervention of initiating levoﬂoxacin pro-
phylaxis in patients with multiple myeloma but not in pa-
tients with lymphoma created a unique setting to examine
the impact of levoﬂoxacin prophylaxis on infectious com-
plications after autologous HSCT. This study design allowed
us to not only examine the rates of infectious complications
before and after the initiation of levoﬂoxacin prophylaxis in
patients with myeloma, but also to make these assessments
in a comparator population of patients with lymphoma who
did not receive the intervention during either time period.
We found that the introduction of levoﬂoxacin prophylaxis
led to a 27% absolute decrease in risk of BSI and a 31% ab-
solute decrease in the risk of FN within 30 days after trans-
plantation. There were no changes in these rates in the
comparator population of patients with lymphoma. Levo-
ﬂoxacin prophylaxis was not associated with increased rates
of bacteremia due to MDR bacterial pathogens, but it was
associated with a nonsigniﬁcant increase in the rates of in-
fections due to C. difﬁcile and ﬂuoroquinolone-resistant
Enterobacteriaceae.
All nonrandomized studies are subject to the potential for
confounding bias. In this study, we believe that the ﬁnding
that rates of BSI and FN were unchanged in a population of
lymphoma patients, who did not receive the intervention of
antibacterial prophylaxis but who otherwise received the
same practices in supportive care and were managed by theSCT in Patients with Multiple Myeloma
ultivariate
sis*
5% CI)
P FN: Univariate
Analysis
OR (95% CI)
P BSI: Multivariate
Analysis*
OR (95% CI)
P
(.14-.51) <.001 .18 (.09-.34) <.001 .18 (0.09-0.36) <.001
(.95-1.02) .29 1.00 (.97-1.03) .83 1.02 (.98-1.05) .36
.71 (.41-1.23) .22
ence Reference
(.50-2.54) .77 1.06 (.51-2.18) .88
(1.03-4.21) .04 1.39 (.70-2.77) .34
.95 (.55-1.65) .87
(.87-1.13) .89 .99 (.90-1.08) .76 .85 (.73-.99) .03
(.76-5.87) .15 1.41 (.62-3.23) .42 1.15 (.33-3.96) .82
1.62 (1.11-2.35) .01 1.31 (.88-1.97) .19
2.94 (.66-13.1) .16
1.40 (.15-12.7) .77
1.76 (.20-15.3) .61
1.11 (.45-2.71) .83
N/Ay
1.54 (.43-5.58) .51
(.94-1.49) .16 3.52 (1.56-7.93) .002 4.31 (1.56-11.9) .005
1.47 (.89-2.44) .13
Reference
.75 (.34-1.68) .48
1.28 (.41-4.01) .67
.70 (.39-1.28) .25
1.02 (.97-1.08) .38
(1.03-1.25) .012 1.15 (1.02-1.31) .02 1.14 (1.01-1.29) .04
us HSCT, duration of neutropenia, and all variables with P  .10 in univariate
ase per Charlson comorbidity index criteria developed FN.
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of our ﬁndings. Another ﬁnding that supports a causal rela-
tionship between levoﬂoxacin prophylaxis and decreased
rates of BSI and FN is that these decreased rates occurred
immediately after the intervention was implemented. If one
were to hypothesize that other factors were responsible for
the decline in BSI and FN ratesdfactors that were speciﬁc to
patients with myelomadthen it would be expected that
these rates would have declined gradually and would
not have decreased immediately after the initiation of levo-
ﬂoxacin prophylaxis. Finally, we conducted multivariate
models that adjusted for potential confounding variables,
such as age, comorbid illnesses, and duration of neutropenia,
and we found that levoﬂoxacin prophylaxis remained inde-
pendently associated with substantially lower odds of BSI
and FN in these analyses.
Although levoﬂoxacin prophylaxis was strongly associ-
ated with lower rates of infectious complications, several
caveats warrant discussion. Despite the fact that levoﬂoxacin
prophylaxis was associated with decreased BSI rates overall,
it was not associated with decreased rates of BSIs compli-
cated by severe sepsis or ICU admission. Perhaps this is
related to our observation that levoﬂoxacin prophylaxis had
a greater impact on rates of BSI due to coagulase-negative
staphylococci and VGS than BSI due to Gram-negative or-
ganisms. Bacteremias due to coagulase-negative staphylo-
cocci and VGS in HSCT recipients are associated with lower
rates of severe sepsis than that which is seen in Gram-
negative bacteremias [17]. Consistent with previous
studies, we also did not identify a mortality beneﬁt associ-
ated with the introduction of levoﬂoxacin prophylaxis. Given
the low short-term mortality rates after autologous HSCT
[18], even if there was a small incremental mortality beneﬁt
to levoﬂoxacin prophylaxis, a larger study would be needed
to detect this effect.
Levoﬂoxacin prophylaxis was associated with a nonsig-
niﬁcant increased risk of developing bacteremia due to
levoﬂoxacin-resistant Enterobacteriaceae. However, anti-
pseudomonal b-lactam agents, not levoﬂoxacin, are recom-
mended for the treatment of fever in neutropenic patients.
Fluoroquinolone use has previously been identiﬁed as a
risk factor for infections caused by pathogens that are
resistant to these b-lactam agents, such extended-spectrum
b-lactamase-producing and carbapenem-resistant Enter-
obacteriaceae [19,20]. However, we did not ﬁnd an associa-
tion between levoﬂoxacin prophylaxis and increased rates
of bacteremia due to either these MDR Gram-negative
pathogens or MDR Gram-positive pathogens, such as
methicillin-resistant S. aureus, penicillin-resistant VGS, and
vancomycin-resistant enterococci. A potential explanation
for these ﬁndings is that levoﬂoxacin prophylaxis was asso-
ciated with a lower incidence of FN and BSI, and, thus, less
use of broad-spectrum b-lactam agents. The absence of an
increase in bacteremias due to these MDR pathogens is
reassuring, but given the ever-changing epidemiology of
resistant organisms, centers that administer levoﬂoxacin
prophylaxis in the myeloma population should continue to
monitor for increasing rates of antibacterial resistance.
Our analysis was inconclusive as to the effect of levo-
ﬂoxacin prophylaxis on the risk of C. difﬁcile infection. There
was a nonsigniﬁcant increase from 3% to 7% in the incidence
of C. difﬁcile infection rates after initiating levoﬂoxacin
prophylaxis in patients with myeloma that was not seen in
patients with lymphoma. Although ﬂuoroquinolones are
risk factors for C. difﬁcile infection [21,22], it is possible thatlower rates of bacteremia and FN led to less exposure to
other antimicrobial agents, which in turn mitigated the ef-
fect of ﬂuoroquinolone prophylaxis on rates of C. difﬁcile
infection. As with antimicrobial resistance, monitoring
for increased rates of C. difﬁcile infection is warranted
with the use of levoﬂoxacin prophylaxis, particularly given
the emergence of virulent NAP1 strains that are ﬂuo-
roquinolone resistant [10].
In addition to the observational nature of the study, other
limitations merit mention. This study was conducted at a
single center where approximately 50% of staphylococci, 75%
of Klebsiella pneumoniae, and 70% of Escherichia coli were
susceptible to levoﬂoxacin during the time of the study. The
effectiveness of levoﬂoxacin prophylaxis may be diminished
at centers with lower rates of levoﬂoxacin susceptibility
among these prominent pathogens and individual centers
should monitor for increases in levoﬂoxacin resistance. It is
possible that the duration of follow-up after the initiation of
ﬂuoroquinolone prophylaxis in this study (3.5 years) was not
sufﬁcient to identify a statistically signiﬁcant increase in
antimicrobial resistance. Although we assessed rates of
bacteremia due to MDR pathogens and C. difﬁcile infection,
we did not assess other potential adverse effects from levo-
ﬂoxacin prophylaxis, such as nausea, diarrhea unrelated
to C. difﬁcile, rash, QT prolongation, tendonitis, and central
nervous system toxicity. A prospective investigation would
be required to properly assess for these potential adverse
effects. Additionally, the ELISA-based assay used to detect
C. difﬁcile infection in the study had lower sensitivity than
current PCR-based tests [23]. It is possible that the lower
sensitivity of this test limited our ability to detect a difference
in rates of C. difﬁcile infection after levoﬂoxacin prophylaxis
was initiated. Finally, we were unable to assess the effec-
tiveness of levoﬂoxacin prophylaxis in patients with lym-
phoma undergoing autologous HSCT because these patients
did not receive levoﬂoxacin prophylaxis during either time
period of the study. We recently started to administer levo-
ﬂoxacin prophylaxis to this population and plan on evalu-
ating the impact of this change in practice in the future.
In summary, we found that the initiation of levoﬂoxacin
prophylaxis was independently associated with lower rates
of BSI and FN in patients with multiple myeloma who un-
derwent autologous HSCT. Patients with lymphoma who
underwent autologous HSCT during the same time period
but did not receive levoﬂoxacin prophylaxis had no changes
in rates of BSI and FN. Furthermore, in patients with
myeloma, levoﬂoxacin prophylaxis was not associated with
increased rates of BSIs due to MDR bacteria, but was
associated with a nonsigniﬁcant increase in the rates of in-
fections due to C. difﬁcile and ﬂuoroquinolone-resistant
Enterobacteriaceae. Based on these ﬁndings, we believe
that levoﬂoxacin prophylaxis should be considered in neu-
tropenic patients with myeloma undergoing autologous
HSCT, with close monitoring for increases in rates of
C. difﬁcile infection and antibacterial resistance.
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